ArticleLancet regional health. Americas2026
A hospital-based retrospective study of hospitalizations with hyalohyphomycosis and phaeohyphomycosis in the United States.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyalohyphomycosis and phaeohyphomycosis are mold infections associated with high mortality rates and diverse clinical presentations, but the epidemiology and outcomes are not well-understood in the United States. We examined hospitalizations associated with their causative fungi to inform potential public health and clinical interventions. Methods: We identified hospitalizations with positive cultures for molds causing hyalohyphomycosis and phaeohyphomycosis using the 2019-2023 Premier Healthcare Database, selecting those in which the patient received at least one dose of a systemic antifungal medication. Findings: We identified 185 hospitalizations associated with Interpretation: Hyalohyphomycosis and phaeohyphomycosis were associated with substantial mortality. Culture-based diagnosis often takes weeks for growth and identification of the causative organism, often leading to inappropriate antifungal treatment while awaiting specific results. Innovation in non-culture-based diagnostics could help improve patient outcomes. Funding: No funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.